Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new therapies to patients faster SAS Clinical Acceleration is now available to ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on RFM stock, giving a Buy rating yesterday. Mani Foroohar has given his Buy rating due to a combination of factors, ...

Innovations in clinical trial designs and tools have the potential to unlock a new era of research that is more convenient for patients, more reflective of real-world treatment conditions, and more ...

In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...